Clinical trial NCT02054871: RCT to Evaluate the Renal Protective Effects of Remote Ischaemic Preconditioning in Peripheral Angioplasty
Official title: Randomised Controlled Trial to Evaluate the Reno-protective Benefits of Remote Ischaemic Preconditioning in Patients Undergoing Infrainguinal Peripheral Angioplasty
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Peripheral Vascular Disease
Keywords: Peripheral Angioplasty
Remote Ischaemic Preconditioning
Contrast Induced Nephropathy
Lead sponsor: Mid Western Regional Hospital, Ireland
Sponsor class: OTHER
First posted: 2014-02-04
Enrollment: 40
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study aims to demonstrate if remote ischaemic preconditioning (RIPC) may confer renal protection in patients undergoing peripheral angioplasty. Patients will be randomised to receive RIPC and biomarkers for renal injury will be analysed post procedure to determine if any protective benefit was obtained.

Detailed description: Ischaemic preconditioning is an endogenous mammalian mechanism whereby a brief period of ischaemia and reperfusion confers resistance to subsequent prolonged ischaemic insults. First observed in the canine heart, subsequent investigators noted that brief ischaemia in remote organs e.g. skeletal muscle, induced protection in key central organs e.g. the heart. This remote ischaemic preconditioning (RIPC) does not require direct interference with the target organs' blood supply. It can be induced using blood pressure cuffs to produce brief episodes of upper limb ischaemia and reperfusion and confers protection upon numerous organs simultaneously. RIPC reduces myocardial injury following aortic aneurysm repair, cardiac surgery and angioplasty. It also reduces adverse ischaemic events up to six months following percutaneous coronary intervention, implying some medium-term effect.

To date ischaemic conditioning has been applied primarily to the heart however animal studies have shown pre conditioning to offer renal protection.

Fikret et al in 2012 in the Renal Protection Trial demonstrated a protective benefit with RIPC from the development of CIN in high risk patients undergoing elective coronary angiography.Whittaker and Przyklenk in 2011 explored this concept retrospectively using data from patients who had undergone emergency angioplasty for ST elevation myocardial infarction. The original trial was a RCT which examined the protective effect of postconditioning on myocardial ischemia. The authors retrospectively examined if study patients treated with multiple coronary balloon inflations had better renal function than patients not exposed to this remote conditioning. They concluded that patients in the conditioning group received 25% more contrast volume than the control group and showed no decline in renal function as demonstrated by examination of glomular filtration rate at day 3 post procedure in comparison to the control group which saw a significant decline in renal function. The need for contrast-based procedures is rising, with increasing numbers of patients undergoing endovascular procedures, as is the incidence of postcontrast renal failure, which has a reported mortality of 34%. The potential use of RIPC therefore to reduce the risk of kidney damage needs further investigation in a prospective study and the PAD patient group who are routinely exposed to contrast administration in angiography are an ideal study group.

Eligibility criteria: Inclusion Criteria:

* Elective intra-arterial, infrainguinal peripheral angiography/angioplasty
* Written informed consent
* Patients \>18yrs of age
* Patients with CKD (Stage2/3) as evidenced by eGFR \<90ml/min/1.73m2

Exclusion Criteria:

* Severe renal impairment eGFR \<30ml/min
* Evidence of acute renal failure or patients on dialysis
* History of previous CIN
* Contraindication to intravenous volume replacement therapy
* Pregnancy
* Patients on glibenclamide or nicorandil (these medications may interfere with RIPC)

Primary outcomes:
measure: Renal impairment
timeFrame: 72 hours post procedural
Secondary outcomes:
measure: Anti-inflammatory effect of RIPC
timeFrame: 3-6 months post recruitment
Other outcomes:
Locations:
city: Limerick
country: Ireland
facility: HSE Mid Western Regional Hospital
Study officials:
affiliation: University of Limerick
name: Stewart Walsh, MCh FRCS
role: PRINCIPAL_INVESTIGATOR
References: